论文信息 - Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. - 字舞流文

Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL.

B. Druker | J. Tyner | B. Chang | B. Hayes-Lattin | E. Lind | Y. Kosaka | D. Latocha | Adam J. Lamble | J. Leonard | K. Byrd | Pavani Malla | A. Lamble | Dorian H Latocha | Jessica T. Leonard